Ethnopharmacological relevance: Hemidesmus indicus (L.) R. Br. ex Schult. (Apocynaceae) is widely used in traditional medicine in the different parts of the Indian subcontinent due to the various biological activities attributed to its different parts, especially the roots. It has traditionally been used for treating snakebites, scorpion stings, diabetes, urinary diseases, dyspnea, menorrhagia, oligospermia, anorexia, fever, abdominal colic and pain, dysentery, diarrhea, cough, rheumatism, headache, inflammation, pyrosis, skin diseases, leprosy, sexually transmitted diseases and cancer. In Ayurveda, the plant is used in the treatment of bone-loss, low body weight, fever, stress, topical wound and psoriasis. Besides, Ayurvedic literature also depicts its use as anti-atherogenic, anti-spasmodic, memory enhancing, immunopotentiating and anti-inflammatory agents.
Aim of the study: In this review, we aim to present a comprehensive update on the ethnopharmacology, phytochemistry, specific pharmacology, and toxicology of H. indicus and its bioactive metabolites. Possible directions for future research are also outlined in brief.
Materials and methods: Popular and widely used international databases such as PubMed, Scopus, Science Direct, Google Scholar and JSTOR were searched and traditional literature were consulted using the various search strings to retrieve a number of citations related to the ethnopharmacology, biological activity, toxicology, quality control and phytochemistry of H. indicus. All studies on the ethnobotany, phtochemistry, pharmacology, and toxicology of the plant up to 2019 were included in this review.
Results: H. indicus has played an important role in traditional Indian medicine (including Ayurveda) and also in European medicine. The main pharmacological properties of H. indicus include hepatoprotective, anti-cancer, anti-diabetic, antioxidant, neuroprotective, anti-ophidian, cardioprotective, nephroprotective, anti-ulcerogenic, anti-inflammatory, and antimicrobial properties. Phytochemical evaluations of the root have revealed the presence of aromatic aldehydes and their derivatives, phenolics, triterpenoids and many other compounds, some of which were attributed to its bioactivity. This review also compiles a list of Ayurvedic formulations and commercial preparations where H. indicus has been used as an active ingredient. We have included the critical assessment of all the papers cited in this manuscript based on experimental observation and other important points which reflect the loop-holes of research strategy and ambiguity in the papers reviewed in this manuscript.
Conclusions: The study presents an exhaustive and updated review on the traditional, pharmacological and phytochemical aspects of H. indicus with notes on its quality control and toxicological information. Although the crude extracts of H. indicus exhibit an array of pharmacological activities, it is high time to identify more active phyto-constituents by bioactivity-guided isolation besides elucidating their structure-activity relationship. More designed investigations are needed to comprehend the multi-target network pharmacology, to clarify the molecular mode of action and to ascertain the efficacious doses of H. indicus. Moreover, H. indicus is not fully assessed on the basis of its safety and efficacy on human. We hope this review will compile and improve the existing knowledge on the potential utilization of H. indicus in complementary and alternative medicine.
Keywords: (E)-nerolidol (Pubchem CID: 5284507); (E,Z)-2,6-nonadienal (129662528); (E,Z)-2,6-nonadienal (Pubchem CID: 643731); 1,8-cineol (Pubchem CID: 2758); 101664025); 2-hydroxy-4-methoxy acetophenone (Pubchem CID: 11092); 2-hydroxy-4-methoxybenzaldehyde (Pubchem CID: 69600); 2-hydroxy-4-methoxybenzoic acid (Pubchem CID: 75291); 2-methoxyphenol (Pubchem CID: 460); 3-hydroxy-4-methoxybenzaldehyde (Pubchem CID: 12127); 3-methoxyphenol (Pubchem CID: 9007); 4-hydroxy-3-methoxybenzaldehyde (Pubchem CID: 1183); Amyl cinnamate (Pubchem CID: 5355854); Aromadendrene (Pubchem CID: 91354); Benzophenone (Pubchem CID: 3102); Benzyl benzoate (Pubchem CID: 2345); Borneol (Pubchem CID: 64685); Denicunine (Pubchem CID: 102014180); Dihydrocarvyl acetate (Pubchem CID: 30248); Emidine (Pubchem CID: 101664026); Ethnobotany; Hemidescine (Pubchem CID; Hemidesmoside A (Pubchem CID: 102581069); Hemidesmoside B (Pubchem CID: 102581070); Hemidesmoside C (Pubchem CID: 102581071); Hemidesmus indicus; Hemidine (Pubchem CID: 101594607); Heminine (Pubchem CID: 102014181); Hemisine (Pubchem CID: 102446078); Hexadecanoic acid (Pubchem CID: 985); Hydroquinone (Pubchem CID: 785); Hyperoside (Pubchem CID: 5281643); Indicine (Pubchem CID: 73614); Isocaryophyllene (Pubchem CID: 5281522); Isoquercetin (Pubchem CID: 5280804); Ledol (Pubchem CID: 92812); Limonene (Pubchem CID: 22311); Linalyl acetate (Pubchem CID: 8294); Lupeol acetate (Pubchem CID: 92157); Medidesmine (Pubchem CID: 102446077); Methyl 2-hydroxy-4-methoxybenzoate (Pubchem CID: 79523); Methyl salicylate (Pubchem CID: 4133); Nerolidol (Pubchem CID: 5284507); Olean-12-en-3α-yl acetate (Pubchem CID: 45044112); Pharmacology; Phytochemistry; Plocoside A (Pubchem CID: 101682679); Pregnane glycoside (Pubchem CID: 163679249); Quality control; Rutin (Pubchem CID: 5280805); Salicylaldehyde (Pubchem CID: 6998); Stigmast-5-en-3β-ol (Pubchem CID: 86821); Terpinen-4-ol (Pubchem CID: 11230); Toxicology; α-bisabolol (Pubchem CID: 1549992); α-muurolol (Pubchem CID: 6430767); α-terpinyl acetate (Pubchem CID: 111037); β-amyrin acetate (Pubchem CID: 92156); β-amyrin palmitate (Pubchem CID: 13915599); β-sitosterol (Pubchem CID: 222284).
Copyright © 2020 Elsevier B.V. All rights reserved.
Declaration of competing interest None.